V. Rijckborst Et Al. , "EARLY ON-TREATMENT HBSAG AND HBV DNA LEVELS IDENTIFY HBEAG-NEGATIVE PATIENTS NOT RESPONDING TO 48 OR 96 WEEKS OF PEGINTERFERON ALFA-2A THERAPY," 61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases , vol.52, Massachusetts, United States Of America, 2010
Rijckborst, V. Et Al. 2010. EARLY ON-TREATMENT HBSAG AND HBV DNA LEVELS IDENTIFY HBEAG-NEGATIVE PATIENTS NOT RESPONDING TO 48 OR 96 WEEKS OF PEGINTERFERON ALFA-2A THERAPY. 61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases , (Massachusetts, United States Of America).
Rijckborst, V., Hansen, B. E., Ferenci, P., Brunetto, M. R., Tabak, F., Cakaloglu, Y., ... Lanza, A. G.(2010). EARLY ON-TREATMENT HBSAG AND HBV DNA LEVELS IDENTIFY HBEAG-NEGATIVE PATIENTS NOT RESPONDING TO 48 OR 96 WEEKS OF PEGINTERFERON ALFA-2A THERAPY . 61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Massachusetts, United States Of America
Rijckborst, Vincent Et Al. "EARLY ON-TREATMENT HBSAG AND HBV DNA LEVELS IDENTIFY HBEAG-NEGATIVE PATIENTS NOT RESPONDING TO 48 OR 96 WEEKS OF PEGINTERFERON ALFA-2A THERAPY," 61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Massachusetts, United States Of America, 2010
Rijckborst, Vincent Et Al. "EARLY ON-TREATMENT HBSAG AND HBV DNA LEVELS IDENTIFY HBEAG-NEGATIVE PATIENTS NOT RESPONDING TO 48 OR 96 WEEKS OF PEGINTERFERON ALFA-2A THERAPY." 61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases , Massachusetts, United States Of America, 2010
Rijckborst, V. Et Al. (2010) . "EARLY ON-TREATMENT HBSAG AND HBV DNA LEVELS IDENTIFY HBEAG-NEGATIVE PATIENTS NOT RESPONDING TO 48 OR 96 WEEKS OF PEGINTERFERON ALFA-2A THERAPY." 61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases , Massachusetts, United States Of America.
@conferencepaper{conferencepaper, author={Vincent Rijckborst Et Al. }, title={EARLY ON-TREATMENT HBSAG AND HBV DNA LEVELS IDENTIFY HBEAG-NEGATIVE PATIENTS NOT RESPONDING TO 48 OR 96 WEEKS OF PEGINTERFERON ALFA-2A THERAPY}, congress name={61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases}, city={Massachusetts}, country={United States Of America}, year={2010}}